Using tranexamic acid to reduce blood loss in breast esthetic surgery
The Effectiveness of Tranexamic Acid in Breast Esthetic Surgery.
PHASE4 · Poznan University of Medical Sciences · NCT05945680
This study is testing if giving tranexamic acid before breast surgery can help reduce blood loss during the procedure.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Sponsor | Poznan University of Medical Sciences (other) |
| Locations | 1 site (Poznań) |
| Trial ID | NCT05945680 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of tranexamic acid (TXA) in reducing blood loss during breast esthetic surgery. It is a randomized placebo-controlled study that compares the outcomes of patients receiving TXA before surgery to those receiving a placebo. The central hypothesis is that TXA will decrease hemorrhage and improve clot stability, thereby minimizing blood loss during the procedure. The study aims to provide valuable data on the use of TXA in plastic surgery, an area where its application is still being explored.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 to 75 scheduled for breast esthetic surgery with an ASA classification of 1 or 2.
Not a fit: Patients with a BMI outside the range of 20 to 35, those with a history of thromboembolism, or those on anticoagulants may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical outcomes and reduced blood loss for patients undergoing breast esthetic procedures.
How similar studies have performed: Previous studies have shown that TXA can effectively reduce blood loss in various surgical settings, suggesting potential success in this novel application within plastic surgery.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * women scheduled for breast esthetic surgery * ASA 1 or 2 * age \>18 and \<75 years Exclusion Criteria: * BMI \<20 or \>35 kg/m2 * ASA 3 or \> 3 * medical history of thromboembolism * history of hematological disease * treatment with aspirin 14 days before the procedure * treatment with anticoagulants 5 days before the procedure * epilepsy * allergy to tranexamic acid * coagulation disorders
Where this trial is running
Poznań
- Poznan University of Medical Sciences — Poznań, Poland (RECRUITING)
Study contacts
- Study coordinator: Małgorzata Domagalska, Ph.D.
- Email: m.domagalska@icloud.com
- Phone: +48 608762068
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hemorrhage, Bleeding